购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Cytochromes P450
    (1)
  • Others
    (4)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (1)
  • 5日内发货
    (2)
  • 35日内发货
    (1)
  • 6-8周
    (1)
筛选
搜索结果
TargetMol产品目录中 "

cyp 40

"的结果
  • 抑制剂&激动剂
    5
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    1
    TargetMol | Recombinant_Protein
  • PKI-179
    T360841197160-28-3
    PKI-179 is a potent and orally active dual PI3K mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo[1][2]. PKI-179 inhibits the cell proliferation, with IC50s of 22 nM and 29 nM for MDA361 and PC3 cells, respectively[1].PKI-179 shows inhibitory activity against a panel of 361 other kinases, hERG and cytochrome P450 (CYP) isoforms at concentrations up to >30 μM, but does have activity for CYP2C8 (IC50=3 μM)[1]. PKI-179 (5-50 mg kg; p.o. once daily for 40 days) inhibits the tumor growth and is well tolerated in nude mice bearing MDA-361 human breast cancer tumors[1].PKI-179 (50 mg kg; p.o.) results in good inhibition of PI3K signaling in nude mice bearing MDA361 tumor xenografts[1].PKI-179 exhibits good oral bioavailability (98% in nude mouse, 46% in rat, 38% in monkey, and 61% in dog) and a high half-life (>60 min) [1]. [1]. Venkatesan AM, et, al. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K) mammalian target of rapamycin (mTOR) inhibitor. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5869-73.[2]. Rehan M. A structural insight into the inhibitory mechanism of an orally active PI3K mTOR dual inhibitor, PKI-179 using computational approaches. J Mol Graph Model. 2015 Nov;62:226-234.
    • ¥ 1220
    5日内发货
    规格
    数量
  • Celecoxib Carboxylic Acid
    T36187170571-01-4
    Celecoxib carboxylic acid is an inactive metabolite of the COX-2 inhibitor celecoxib .1,2It is formed from celecoxib primarily by the cytochrome P450 (CYP) isoform CYP2C9. 1.Liu, H., Huang, X., Shen, J., et al.Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: Molecular docking and 3D QSAR analysesJ. Med. Chem.45(22)4816-4827(2002) 2.Kim, S.-H., Kim, D.-H., Byeon, J.-Y., et al.Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metaboliteArch. Pharm. Res.40(3)382-390(2017)
    • 待估
    35日内发货
    规格
    数量
  • hiv-1 inhibitor-40
    T62452
    HIV-1 inhibitor-40 (Compound 4ab) 是一种 HIV-1 非核苷型逆转录酶抑制剂 (NNRTI) (EC50: 1.9 nM),体内没有明显急性毒性。HIV-1 inhibitor-40CYP 的敏感性较低,作用于 CYP2C9 (IC50: 5.16 μM) 和 CYP2C19 (IC50: 4.51 μM)。
    • ¥ 10600
    10-14周
    规格
    数量
  • TP0472993
    T679162126874-77-7
    TP0472993 是一种有效的和具有口服活性的细胞色素 P450 (CYP) 4A11 和 CYP4F2 的双重抑制剂,IC50 值分别为 140 nM 和 40 nM。TP0472993 可从肝脏和肾脏中提取, 具有治疗肾脏疾病的潜力。
    • ¥ 445
    In stock
    规格
    数量
  • desethoxy quetiapine hydrochloride
    O-Desalkylquetiapine
    T84947329218-14-6
    Desethoxy quetiapine, an active metabolite of the atypical antipsychotic quetiapine, primarily forms through the action of the cytochrome P450 (CYP) isoform CYP3A5. This compound binds to dopamine D2 receptors with an IC50 value of 1,330 nM. In vivo, desethoxy quetiapine at dosages of 20 and 40 mg kg mitigates dopamine receptor agonist apomorphine-induced climbing behavior and ameliorates swimming deficits in mice, showcasing its potential modulatory effects on dopamine-mediated behaviors.
    • 待询
    8-10周
    规格
    数量